参考文献/References:
[1] Mizrahi JD,Surana R,Valle JW,et al.Pancreatic cancer[J].Lancet,2020,395(10242):2008-2020.DOI:10.1016/S0140-6736(20)30974-0.
[2] Siegel RL,Miller KD,Fuchs HE,et al.Cancer statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.DOI:10.3322/caac.21654.
[3] Gallo M,Adinolfi V,Morviducci L,et al.Early prediction of pancreatic cancer from new-onset diabetes:an Associazione Italiana Oncologia Medica(AIOM)/Associazione Medici Diabetologi(AMD)/Società Italiana Endocrinologia(SIE)/Società Italiana Farmacologia(SIF)multidisciplinary consensus position paper[J].ESMO Open,2021,6(3):100155.DOI:10.1016/j.esmoop.2021.100155.
[4] Soliman GA,Shukla SK,Etekpo A,et al.The synergistic effect of an ATP-competitive inhibitor of mTOR and metformin on pancreatic tumor growth[J].Curr Dev Nutr,2020,4(9):nzaa131.DOI:10.1093/cdn/nzaa131.
[5] Menini S,Iacobini C,de Latouliere L,et al.The advanced glycation end-product N-carboxymethyllysine promotes progression of pancreatic cancer:implications for diabetes-associated risk and its prevention[J].J Pathol,2018,245(2):197-208.DOI:10.1002/path.5072.
[6] Luo J,Xiang Y,Xu X,et al.High glucose-induced ROS production stimulates proliferation of pancreatic cancer via inactivating the JNK pathway[J].Oxid Med Cell Longev,2018,2018:1-10.DOI:10.1155/2018/6917206.
[7] Toledo F,Chari S,Yadav D.Understanding the contribution of insulin resistance to the risk of pancreatic cancer[J].Am J Gastroenterol,2021,116(4):669-670.DOI:10.14309/ajg.0000000000001104.
[8] Leroith D,Holly JMP,Forbes BE.Insulin-like growth factors:ligands,binding proteins,and receptors[J].Mol Metab,2021,52:101245.DOI:10.1016/ j.molmet.2021.101245.
[9] Hua H,Kong Q,Zhang H,et al.Targeting mTOR for cancer therapy[J].J Hematol Oncol,2019,12(1):71.DOI:10.1186/s13045-019- 0754-1.
[10] Paternoster S,Falasca M.The intricate relationship between diabetes,obesity and pancreatic cancer[J].Biochim Biophys Acta Rev Cancer,2020,1873(1):188326.DOI:10.1016/j.bbcan.2019.188326.
[11] Quoc Lam B,Shrivastava SK,Shrivastava A,et al.The impact of obesity and diabetes mellitus on pancreatic cancer:molecular mechanisms and clinical perspectives[J].J Cell Mol Med,2020,24(14):7706-7716.DOI:10.1111/jcmm.15413.
[12] Desai V,Patel K,Sheth R,et al.Pancreatic fat infiltration is associated with a higher risk of pancreatic ductal adenocarcinoma[J].Visc Med,2020,36(3):220-226.DOI:10.1159/000507457.
[13] Sharma A,Kandlakunta H,Nagpal SJS,et al.Model to determinerisk of pancreatic cancer in patients with new-onset diabetes[J].Gastroenterology,2018,155(3):730-739.e3.DOI:10.1053/j.gastro.2018.05.023.
[14] Dong X,Lou YB,Mu YC,et al.Predictive factors for differentiating pancreatic cancer-associated diabetes mellitus from common type 2 diabetes mellitus for the early detection of pancreatic cancer[J].Digestion,2018,98(4):209-216.DOI:10.1159/000489169.
[15] Choe JW,Kim HJ,Kim JS,et al.Usefulness of CA19-9 for pancreatic cancer screening in patients with new-onset diabetes[J].Hepatobiliary Pancreat Dis Int,2018,17(3):263-268.DOI:10.1016/j.hbpd.2018.04.001.
[16] Bosetti C,Rosato V,Li D,et al.Diabetes,antidiabetic medications,and pancreatic cancer risk:an analysis from the International Pancreatic Cancer Case-Control Consortium[J].Ann Oncol,2014,25(10):2065-2072.DOI:10.1093/annonc/mdu276.
[17] Lee DY,Yu JH,Park S,et al.The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer:a nationwide population-based study in Korea[J].Sci Rep,2018,8(1):9719.DOI:10.1038/s41598-018-27965-2.
[18] Lin CM,Huang HL,Chu FY,et al.Association between gastroenterological malignancy and diabetes mellitus and anti-diabetic therapy:a nationwide,population-based cohort study[J].PLoS One,2015,10(5):e0125421.DOI:10.1371/journal.pone.0125421.
[19] Wang G,Yin L,Peng Y,et al.Insulin promotes invasion and migration of KRASG12D mutant HPNE cells by upregulating MMP-2 gelatinolytic activity via ERK- and PI3K-dependent signalling[J].Cell Prolif,2019,52(3):e12575.DOI:10.1111/cpr.12575.
[20] Monami M,Nreu B,Scatena A,et al.Safety issues with glucagon-like peptide-1 receptor agonists(pancreatitis,pancreatic cancer and cholelithiasis):data from randomized controlled trials[J].Diabetes Obes Metab,2017,19(9):1233-1241.DOI:10.1111/dom.12926.
[21] 田勍,刘烨,路然,等.2型糖尿病患者中肠促胰素药物与胰腺癌风险:随机对照试验的Meta分析[J].中华糖尿病杂志,2017,9(12):751-757.DOI:10.3760/cma.j.issn.1674-5809.2017.12.005.
[22] Tang H,Yang K,Li X,et al.Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus:a systematic review and meta-analysis[J].Pharmacoepidemiol Drug Saf,2020,29(2):161-172.DOI:10.1002/pds.4943.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(06):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(06):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(06):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(06):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(06):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]